Last reviewed · How we verify
Pre-stroke antihypertensives
Pre-stroke antihypertensives is a Antihypertensive (acute stroke therapy) Small molecule drug developed by University of Nottingham. It is currently in Phase 3 development for Acute ischemic stroke with elevated blood pressure, Acute hemorrhagic stroke with hypertension.
Pre-stroke antihypertensives are blood pressure-lowering agents designed to be administered acutely before or immediately after a stroke event to reduce neurological damage.
Pre-stroke antihypertensives are blood pressure-lowering agents designed to be administered acutely before or immediately after a stroke event to reduce neurological damage. Used for Acute ischemic stroke with elevated blood pressure, Acute hemorrhagic stroke with hypertension.
At a glance
| Generic name | Pre-stroke antihypertensives |
|---|---|
| Sponsor | University of Nottingham |
| Drug class | Antihypertensive (acute stroke therapy) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
These agents work by reducing systemic blood pressure in the acute stroke window, which may help limit cerebral edema, prevent hemorrhagic transformation, and reduce infarct expansion. The mechanism leverages the principle that controlled blood pressure reduction in the hyperacute phase can improve stroke outcomes, though the exact molecular targets depend on the specific agent used within this class.
Approved indications
- Acute ischemic stroke with elevated blood pressure
- Acute hemorrhagic stroke with hypertension
Common side effects
- Hypotension
- Worsening stroke outcome from excessive BP reduction
- Renal dysfunction
Key clinical trials
- Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion (PHASE3)
- Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management (PHASE2)
- Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II) (PHASE3)
- Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke (NA)
- BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations? (NA)
- Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pre-stroke antihypertensives CI brief — competitive landscape report
- Pre-stroke antihypertensives updates RSS · CI watch RSS
- University of Nottingham portfolio CI
Frequently asked questions about Pre-stroke antihypertensives
What is Pre-stroke antihypertensives?
How does Pre-stroke antihypertensives work?
What is Pre-stroke antihypertensives used for?
Who makes Pre-stroke antihypertensives?
What drug class is Pre-stroke antihypertensives in?
What development phase is Pre-stroke antihypertensives in?
What are the side effects of Pre-stroke antihypertensives?
Related
- Drug class: All Antihypertensive (acute stroke therapy) drugs
- Manufacturer: University of Nottingham — full pipeline
- Therapeutic area: All drugs in Neurology / Cardiovascular
- Indication: Drugs for Acute ischemic stroke with elevated blood pressure
- Indication: Drugs for Acute hemorrhagic stroke with hypertension
- Compare: Pre-stroke antihypertensives vs similar drugs
- Pricing: Pre-stroke antihypertensives cost, discount & access